Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
USP30 antisense RNA 1 (USP30-AS1)
- Target
- USP30-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
USP30 antisense RNA 1 (USP30-AS1) is a human long non-coding RNA (lncRNA) transcribed antisense to the USP30 gene locus. It functions as an epigenetic and post-transcriptional regulator, controlling diverse cellular processes, including mitochondrial homeostasis and mitophagy. USP30-AS1 plays distinct, context-dependent roles in cancer and immune responses: it serves as a negative regulator of mitophagy in glioblastoma, correlating with poor survival, and maintains leukemia cell viability in acute myeloid leukemia, acting as a pro-survival oncogenic regulator[1]. In viral infection settings, USP30-AS1 is robustly upregulated as an interferon-stimulated gene and may participate in the JAK-STAT pathway response; its upregulation suppresses viral protein synthesis, thus modulating host–pathogen interactions[2]. Mechanistically, USP30-AS1 can act in cis to regulate the neighboring USP30 gene and can modulate immune evasion in leukemia by interfering with HLA-I trafficking[1]. Upregulation or knockdown affects cell proliferation and apoptosis depending on the tissue context, and it has value as a disease biomarker in multiple settings[1][2].
- Other names
- USP30-AS1lncRNA USP30-AS1Long non-coding RNA USP30 antisense RNA 1
02
Biological functions
Regulation of mitochondrial homeostasisEpigenetic and post-transcriptional gene regulationModulates immune response (interferon-stimulated)Regulation of mitophagyApoptosis modulationCell proliferation regulation
03
Disease associations
CancerGlioblastomaAcute myeloid leukemiaInfection (specifically, influenza A virus and interferon response)Other
04
Safety considerations
Therapeutic targeting may alter fundamental cellular pathways, such as apoptosis and immune response, raising concern for unintended effects on normal cells[1][2].The complexity and tissue specificity of lncRNA function introduces challenges for targeted therapy and off-target effects may be difficult to predict[1][2].
05
Biomarkers
Biomarker for prognosis in glioblastoma (high levels correlate with poor survival)Biomarker for adverse prognosis in acute myeloid leukemia (overexpressed via hypomethylation and correlates with poor outcome)
Beyond the preview
Go deeper on USP30 antisense RNA 1 (USP30-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USP30 antisense RNA 1 (USP30-AS1).